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Summary.-m-AMSA is an intercalating agent at present on Phase II trial as a
chemotherapeutic drug. A 30min exposure of Chinese hamster (Line V79-753B) cells
to submicromolar concentrations of m-AMSA killed 50%O of the cells. The survivors
had an enhanced sensitivity to radiation-induced cell killing. Depending upon the
conditions, m-AMSA enhanced the radiation effect by either a decrease in the
survival-curve shoulder or by an increase in slope. m-AMSA may act partly by
suppressing the accumulation of sublethal damage but, if so, recovery from damage
as measured in split-dose experiments with cells pretreated with the drug is not
affected. m-AMSA increased radiation lethality throughout the cell cycle, but a con-
tribution to its radiation effect from selective toxicity to cells in a radioresistant
phase of the cell cycle cannot be excluded. Radiation and the drug interacted to give
increased cell killing, even when the exposures to each agent were separated in time.
It is concluded that m-ASMA may behave like actinomycin D and adriamycin, and
enhance clinical radiation responses. In vivo testing to determine the effect of
m-AMSA on the therapeutic index is recommended.
AMONG THE NEW CYTOTOXIC AGENTS
that therapists hope will extend the range
of cancer chemotherapeutic drugs are the
9-anilinoacridines developed by Cain and
his co-workers (Denny et al., 1978, and
references therein). Reversibility ofmyelo-
suppression and limited other side effects
are attractive features of m-AMSA (4'-
[9 - acridinylamino] - methanesulphon - m -
anisidide) the derivative on which atten-
tion has been focused initially.
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m-AMSA (NSC249992)
m-AMSA is now on Phase II trial in the
U.S.A. and Europe, and the encouraging
preclinical and Phase I data have been
reviewed (Rozeneweig et al., 1979). Al-
though the mechanism of action of the
drug is uncertain, it is probable that its
ability to bind to DNA by intercalation
(Waring, 1976) is involved. Tobey et al.
(1978) have shown that mammalian cells
in vitro have a similar response to
m-AMSA and to Adriamycin (ADR),
another intercalating agent. This has
caused the 9-anilinoacridines to be placed
in the category of cytotoxic intercalating
agents such as ADR and actinomycin D
(AMD).
Many cytotoxic drugs have effects that
are non-interactive with the cell-killing
effects of radiation, while others actually
enhance the ability of radiation to kill
cells. This is one reason for the current
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interest in combined chemotherapy-
radiotherapy treatments. Intercalating
agents such as ADR and AMD are notable
in that enhancement has been observed in
many tissues, both normal and malignant
(Phillips & Fu, 1979). These drugs also
display the "recall" phenomenon whereby
enhancement of damage occurs even when
the drug and radiation exposures are
widely separated in time (D'Angio, 1962;
Donaldson et al., 1974). It is of obvious
importance to establish whether m-AMSA
interacts with radiation damage under
clinical conditions, and to investigate
whether any interaction is likely to be
therapeutically useful or disadvantageous.
As a first step the interaction has been
studied in vitro. An earlier paper showed
that the drug sensitized irradiated bac-
terial cells by removing the shoulder on
the survival curve (Roberts et al., 1979).
Here we report the results with mam-
malian cells.
METHODS
in-AMSA was kindly supplied by Dr B. F.
Cain and made up in distilled water just
before use. Concentrations were measured
spectrophotometrically at 433 nm (E=1120
m2/mol) and then diluted into medium or
Dulbecco's phosphate-buffered saline "A"
(PBSA) as required. The drug had a half-life
in PBSA and in medium of at least 10 h, as
judged by the retention ofoptical absorbance
and drug toxicity.
Chinese hamster cells, Line V79-753B,
were maintained as asynchronous exponen-
tial cultures in 4oz medical flats in Earle's
minimal essential medium supplemented with,
15% foetal calf serum and 14 mm HEPES
buffer as described previously (Cooke et al.,
1976). For experiments, cells were harvested,
resuspended in fresh growth medium and
plated on to 60mm glass Petri dishes (2 x 102
to 104 cells/dish) in a total volume of 2 ml of
growth medium. When the cells had attached
to the glass, the medium was aspirated from
the dishes and replaced with 2 ml of fresh
growth medium or PBSA with or without
m-AMSA as appropriate. Triplicate dishes
were placed in "Dural" containers, gassed
with "white spot" N2 for 1 h if 02 was to be
removed, and sealed before irradiation.
Irradiations were carried out using a 60Co
source and a dose rate of about 4 Gy/min.
Unless otherwise indicated, the cultures were
replenished after irradiation with 2 ml of
fresh growth medium and incubated for 7
days at 37°C in an atmosphere of 5% CO2-
95% air to permit colony formation. The
medium was then removed from the dishes,
and the colonies were fixed with ethanol,
stained with methylene blue and counted.
For experiments involving synchronized
cells, 1 25mM hydroxyurea in full growth
medium was added to cells which had been
plated on to dishes 16 h previously and incu-
bated at 37°C. After 5 h the hydroxyurea was
replaced with fresh drug-free medium and the
surviving cells proceeded through the cycle
from the G1-S boundary.
All experiments were done at least twice,
and in survival-curve experiments the pooled
data were analysed by regression analysis to
the multi-target equation using a CDC 400
computer (Millar et al., 1978). The para-
meters from the regression analysis were sub-
jected to a minimizing subroutine to obtain
values for Do, n, Dq and errors (Powell, 1971).
These values were used in a second pro-
gramme (J. L. Millar, unpublished) to give
theoretical curves from the computed data.
Data were analysed in this way to remove
subjective bias. It is not intended that the
multi-target equation used should be the
best possible fit of the data (see Millar et al.,
1978).
Technical difficulties found in experiments
with other intercalating agents have included
the binding of these drugs to plastic or glass
Petri dishes, and the slow release ofthe drugs
from killed cells. Similar problems were not
encountered with m-AMSA under our con-
ditions, but to minimize any possible toxic
effect due to the slow release of drug, the
maximum number of cells plated per dish
was 104.
RESULTS AND DISCUSSION
Survival curvesfor asynchronous cells
Investigations of the interaction be-
tween radiation and m-AMSA are re-
stricted to submicromolar drug concentra-
tions since, as Fig. 1 shows, m-AMSA is
highly toxic to mammalian cells. The
curves in Fig. 1 are similar to those for
ADR (Byfield et al., 1977; Belli & Piro,
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FIG. 1.-The cytotoxic effect of different
concentrations of m-AMSA on V79-753B
cells treated for 30 min (0) or 120 min
(0) in PBSA. Results in medium were
similar, but about twice the concentration
was required for equal toxicity.
1977). In view ofthe toxicity of m-AMSA,
when cells were irradiated in combination
with the drug the surviving fractions were
calculated by normalizing the observed
survivors to the number of survivors in
unirradiated cultures that had been ex-
posed to the drug for a similar length of
time. This allowed cytotoxicity and the
radiation response of drug-treated cells to
be separated.
The m-AMSA treatment used most
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FIG. 2.-Enhanced radiation-induced cell kill-
ing in the survivors of a 30min exposure to
0-2AM m-AMSAinPBSA. Drugpresent dur-
ing irradiation. Points are the means of
different experiments and the error bars
indicate the range of values where this is
greater than the size ofthe data point.
O No drug
* 0.2 ,Lg drug
D0(rad)
164 + 9
153+ 9
n Dq(rad)
7-8 + 2-3 337 + 66
3-3+1-0 183+56
frequently was a 30min exposure at room
temperature to a concentration of 0-2 ,M
( 0-1 ,g/ml) in PBSA. This reduced the
plating efficiency to 40-60% of the un-
treated controls. Fig. 2 shows that after
this drug exposure the killing of surviving
cells by radiation was enhanced. The
enhancement was characterized by a
TABLE.-The effect of m-AMSA on survival-curve parameters*
[Drug] ,uM Conditions
PBSA/air
0-2 PBSA/air
0-8 PBSA/air
Medium/air
0-2 Medium/air
0-35 Medium/air
PBSA/N2
0-2 PBSA/N2
Do (Gy)
1-64 + 0-09
1-53 + 0-09
1-20+ 0-17
1-66 + 0-07
1-49+0-10
1-11+0-11
5-52 + 0-28
4-28 +0-30
n
7-8+2-3
3-3+1-0
7-1+5-5
7-5+ 1-6
4-6+1-5
8-3+4-6
3-4+0-9
1-9+0-6
Dq (Gy)
3-37 + 0-66
1-83+0-56
2-36+0-60
3-35 + 0-51
2-24+ 0-62
2-35 + 0-83
6-80+ 1-06
2-85 + 1-09
P.E.
1-0
0-4-0-6
0-2-0-35
1-0
0-8
0-5
1-0
0-8
* + s.e. obtained as outlined in Methods.
P.E. =plating efficiency normalized to a value of 1 0 without drug.
Drug exposures were for 30 min before irradiation in air and for the 1 h degassing period in N2.
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decrease in the survival-curve parameters
n (the extrapolation number) and Dq,
which indicates the width of the shoulder
on the curve. No significant change
occurred in the final slope, D, A lower
m-AMSA concentration (0.08 klM) was not
toxic and did not enhance radiation
effects. When cells were exposed to 0-2/MA
drug for less than 5 min, there was again
insignificant toxicity and no enhancement
of radiation-induced lethality. A 30min
exposure to a 4-fold higher concentration
(0.8 ,iM) reduced the plating efficiency to
20-35%. There is a significant decrease in
the Do of cells surviving this higher con-
centration of m-AMSA (Table), in con-
trast to cells surviving 0-2 ELM.
When cells were exposed for 30 min to
m-AMSA at room temperature in full
growth medium, the toxicity was less than
in cells exposed to similar drug concentra-
tions in PBSA. The radiation killing of
cells that had been exposed to 0-2juM
m-AMSA in full growth medium was
enhanced, with a decrease in all 3 para-
meters n, Dq and Do (Table). When cells
were irradiated after a 30min exposure to
0-35[M m-AMSA, a drug concentration in
medium that produced similar toxicity to
that in cells exposed to 02[kM of the drug
in PBSA, the decrease in cell survival was
mainly due to a change in D,. The Table
also shows that m-AMSA increased radia-
tion-induced cell killing under hypoxic
conditions. Reductions in n, Dq and Do
were found after drug treatment. Appar-
ently m-AMSA can interact with radiation
damage in both aerobic and hypoxic cells,
giving similar increases in cell killing.
Tissue hypoxia per se is unlikely to pro-
tect irradiated tissues or tumours against
enhancement by m-AMSA, nor will it be
the basis of a differential gain in tumours.
In summary, a drug concentration that
is moderately toxic in PBSA reduces the
size of the shoulder, but at higher concen-
trations, or in full growth medium or in
hypoxia, changes in Do are apparent. The
ability of the experimental conditions to
determine whether changes in n or Do
describe the enhancement of radiation
effects is not unique to m-AMSA. Other
intercalating agents exhibiting similar
behaviour are AMD (Elkind & Whitmore,
1967), ADR (compare Belli & Piro, 1977,
with Byfield et al., 1977) and quinacrine
(Saladino & Ben-Hur, 1978).
Timing of the drgu and radiation treatments
The intercalating drugs AMD and ADR
display a "recall" phenomenon, in which
an enhanced clinical response is observed
even when the drug and radiation treat-
ments are separated in time (D'Angio,
1962; Donaldson et al., 1974). In vitro,
more than additive cell killing occurs with
time-separated treatments (Belli & Piro,
1977; Piro et al., 1975). Similarly, we have
found that exposures to m-AMSA and
radiation need not be simultaneous for an
interaction to occur. Fig. 3 shows that cell
killing was enhanced even if cells were
maintained in drug-free PBSA at 37°C for
a period between sequential treatments in
which the drug exposure was followed
some time later by 7.4 Gy or vice versa.
Positive times refer to the interval be-
tween irradiation and a 30min exposure
to 0-2/M m-AMSA. Negative times refer
to the interval spent in drug-free PBSA
after a drug exposure and before irradia-
tion. An m-AMSA treatment given before
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FIG. 3. The interaction between m-AMSA
and radiation clamage when the drug was
not present during irradiation (7.4 Gy). The
solid line arbitrarily joins the surviving
fractions expected for untreated, irradiated
control cells (A) and cells irradiated in the
presence of (irug at the end of the drug
treatment (B).
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radiation remained fully effective for at
least 2 h after the drug had been removed.
Enhanced cell killing was also found when
the drug followed the radiation, but only
if the treatments were less than about 2 h
apart. The time course for the loss of a
post-irradiation interaction is similar to
that found with AMD (Elkind et al., 1968)
but it differs from the response found with
ADR, for which an increased interaction
was shown as the post-irradiation interval
increased up to 2 h (Belli & Piro, 1977).
The lossofinteractionfound with m-AMSA
given after irradiation could be due to
recovery from sublethal radiation injury,
as suggested by Elkind et al. (1968) for
AMD (see next section).
The effect of mn-AMSA on Elkind-Sutton
recovery
Enhanced radiation killing of cells ex-
posed to intercalating agents such as
ADR, AMD and quinacrine has usually
been apparent, at least in part, as a
decrease in the shoulder ofthe cell-survival
curve. The decrease has been attributed
usually to a reduced ability to accumulate
sublethal damage as a result of exposure
to the drug (e.g. Elkind et al., 1967; Belli &
Piro, 1977). m-AMSA is an intercalating
agent (Waring, 1976) and interferes with
DNA synthesis and nucleic acid poly-
merases (Gormley et al., 1978) and a
similar explanation may be reasonable for
the results reported above. It was of
interest to determine whether m-AMSA
could suppress the recovery process that
occurs when cells are incubated in medium
at 37°C between two radiation doses
(Elkind - Sutton recovery). Conditions
were used that most clearly enhanced
radiation effects via a decrease in the
shoulder of the survival curve. Before the
first radiation dose, cells were exposed to
021uM m-AMSA in PBSA at room tem-
perature. After irradiation the drug was
replaced with full growth medium and
incubated at 370C for various times to
allow for recovery, followed by a second
radiation dose. Fig. 4 shows that there
was no difference between cells pre-
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FiG. 4. Recovery of viability in control cells
given an initial 7 Gy dose and in cells
exposed1 to O-21mm-AMSA in PBSA(30min)
before an initial 5 Gy dose. After the re-
covery intervals slhown both, sets of cells
were given a secon(l dose of 3 Gy.
treated with m-AMSA and untreated
control cells, either in the time course or
in extent of recovery. Therefore, if
m-AMSA pre-treatment does suppress the
accumulation of sublethal damage, it does
not interfere with Elkind-Sutton re-
covery. In this it resembles ADR (Belli &
Piro, 1977) and differs from AMD (Elkind
et al., 1964). Whatever the actual mech-
anism, it should be noted that, for at least
two intercalating drugs, an apparent de-
crease in the size of the initial shoulder is
not directly linked to suppression of re-
covery between successive doses.
Synchronised cells
In this work m-AMSA enhanced radia-
tion damage only under conditions that
were also toxic to the cells. An alternative
explanation for the action of m-AMSA
could be that the drug alters the distribu-
tion of cells in the cell cycle, resulting in a
cell population that is more radiation-
sensitive than a normal, asynchronous
population. This could occur, for example,
if the drug is particularly toxic to cells in
late S, the most radioresistant phase ofthe
cell cycle (Sinclair, 1968). Evidence sup-
porting such a mechanism has been found
by Wilson & Whitmore (in preparation).
A preliminary study has been made
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efficiency to 0-38. Fig. 5.
cytotoxicity caused by
exposure to 02,uM m-AIV
cells progressed througl
Thus, m-AMSA treatm
chronous population cai
alter the distribution of
cell cycle. However, Fig.
radiation-induced cell ki
the phase of the cell cy
with m-AMSA (Fig. 5A
radiation-response curve
treated cells (Fig. 5B) %
resistance in late S. m-AMSA enhanced
radiation killing throughout the cell cycle
in those cells that survived m-AMSA
cytotoxicity. Maximum resistance to
radiation does not appear to coincide with
maximum m-AMSA cytotoxicity under
our conditions. Clearly, further work with
a cell population having a particularly
narrow age distribution is required to
define the possible contribution from
phase-specific cytotoxicity to the en-
hanced cell killing found with asyn-
chronous populations. We note, however,
that our experiments involved acute ex-
posures to mildly toxic doses. In vivo,
prolonged exposures and highly toxic
doses are likely, and partial synchroniza-
tion by the drug may well contribute to
changes in radiation sensitivity.
Comparison ofthe results with likely clinical
drug levels
6 8 10 12 The pharmacology of m-AMSA has
removing block been investigated in rodents. The drug is
well distributed in all tissues except the
sed at different brain (Cysyk et al., 1977). It is under
(average of two clinical evaluation in Phase II trials, and
Lirradiated, drug- doses in the range 40-120 mg/M2 have
eated cells given been recommended in good-risk patients, 6t each time to a
led cells. (B) Con- depending on the frequency of adminis-
drug-free PBSA tration (see review by Rozeneweig et al.,
1979). In a series of patients given 90 mg/
m2, an average peak plasma concentration
d at the Gl-S of12-3juM was found. The drug was cleared
ea (see Methods). rapidly within the first hour to a level of
)r the average cell 4*6 ,uM, but the concentration subse-
)r the toxicity of quently fell more slowly, and concentra-
reduced plating tions near micromolar were maintained
A shows that the for several hours. Our data indicate that
the usual 30min concentrations as low as 0-2 ,uM (-01
ISA varied as the mg/ml) enhance the radiation killing of
hi the cell cycle. cells. Thus any patient undergoing treat-
ent of an asyn- ment with m-AMSA may have prolonged
a be expected to periods in which tissue levels of the drug
f cells within the will be in excess of that found to enhance
5 also shows how radiation effects in vitro.
illing varies with
rcle. Cells treated
L) have a similar
3 to that of un- At concentrations likely to be en-
with a maximum countered clinically, m-AMSA enhanced
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radiation-induced cell killing in a mam-
malian cell line. The enhancement is
apparent as a decrease in the size of the
shoulder (Dq) or, under some conditions,
an increased slope of the cell-survival
curve (Do). m-AMSA may act partly by
inhibiting the accumulation of sublethal
injury. However, drug pretreatment does
not suppress recovery from damage as
measured in split-dose experiments. Al-
though m-AMSA enhanced radiation dam-
age throughout the cell cycle, a contribu-
tion to its effect on irradiated asyn-
chronous cell populations from selective
cytotoxicity to some phases of the cell
cycle cannot be excluded. Simultaneous
exposures to the drug and radiation are
not required for increased cell killing, but
if the drug is given second, it is not
effective more than 2 h after irradiation.
The results bear many similarities to
findings with other intercalating drugs
that enhance radiation response in several
human tissues. Caution would seem indi-
cated if m-AMSA is to be administered to
patients who have recently received, or
will shortly undergo, radiotherapy. Our
in vitro data indicate that tissue hypoxia
per se will neither protect irradiated tissues
and tumours against m-AMSA, nor be a
basis for a differential gain in tumours.
Any therapeuticgainfromthe combination
of radiotherapy and m-AMSA is likely to
arise from differential uptake/retention in
tumours and normal tissue. Such a differ-
ential has been suggested for melanotic
tissues (Shoemaker et al., 1978). Experi-
ments are required to test whether
m-AMSA interacts with radiation damage
in vivo and to decide whether any inter-
action observed will cause a gain or loss in
the therapeutic index.
This work would not have been possible without
the generous cooperation and support of Professor
G. E. Adams and Dr E. M. Fielden of the Radio-
biology Unit, Institute of Cancer Research to
P.B.R. while the latter was on study leave at the
Institute.
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